About this trial
Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a chronic inflammatory skin disease characterized by scaly indurated erythema.
Psoriatic arthritis (PsA) is an autoimmune and chronic musculoskeletal disorder that is associated with psoriasis of the skin . Its presentation can vary from subtle manifestations to highly destructive forms. Joint pain, stiffness and swelling are the most common symptoms.
Eligibility criteria
Qualifiers
Patients aged 18 years and above.
Patients having psoriasis diagnosed clinically and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score from 5- 10 % of body surface area, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis
Disqualifiers
Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
Pregnancy and lactation.
Patients currently undergoing immunosuppressive or systemic therapies.
Patients with known genetic disorders affect immune system function.
Trial design
Treatments tested in this trial
- Methotrexate
- Placebo